Insider Buying: Retension Pharmaceuticals (NASDAQ:RTSN) CEO Acquires 20,800 Shares of Stock

Retension Pharmaceuticals, Inc. (NASDAQ:RTSN) CEO Eric Keller bought 20,800 shares of the stock in a transaction that occurred on Tuesday, October 13th. The shares were purchased at an average price of $12.00 per share, for a total transaction of $249,600.00. Following the completion of the acquisition, the chief executive officer owned 423,377 shares of the company’s stock, valued at $5,080,524. The trade was a 5.17% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Retension Pharmaceuticals Trading Up 2.7%

RTSN stock traded up $0.31 during trading hours on Tuesday, reaching $11.63. The stock had a trading volume of 137,519 shares, compared to its average volume of 157,559. Retension Pharmaceuticals, Inc. has a fifty-two week low of $9.66 and a fifty-two week high of $12.50.

Retension Pharmaceuticals Company Profile

We are a clinical-stage biopharmaceutical company focused on developing medicines for the treatment of hypertension and other cardiovascular diseases. Our product candidate, RTN-001, is a next-generation, once-daily, oral, small molecule phosphodiesterase-5 (“PDE-5”) inhibitor designed to reduce blood pressure by potentiating nitric oxide signaling, a key mechanism underlying the development and severity of hypertension. While first-generation PDE-5 inhibitors, such as Viagra (sildenafil), were originally studied in cardiovascular indications such as hypertension and angina, we believe they did not have adequate bioavailability and tissue penetration to impact the smooth muscle cells of the central vascular and cardiac tissues and thus failed to achieve clinically meaningful reductions in blood pressure.